Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib in Neoadjuvant Therapy of HER2-positive Early Breast Cancer
NCT04290793Phase 3Active, not recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Mar 2020
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of pyrotinib in breast cancer, sponsored by The Fourth Hospital of Hebei Medical University. Started Mar 2020; status: active, not recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04290793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04290793.